ciprofloxacin has been researched along with Abdominal Abscess in 12 studies
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.
ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.
Abdominal Abscess: An abscess located in the abdominal cavity, i.e., the cavity between the diaphragm above and the pelvis below. (From Dorland, 27th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Microorganisms, their ciprofloxacin resistance, and clinical outcomes were retrospectively analyzed in 78 CD patients with intra-abdominal abscesses, who underwent percutaneous drainage between March 1991, and November 2011." | 3.80 | Ciprofloxacin usage and bacterial resistance patterns in Crohn's disease patients with abscesses. ( Byeon, JS; Duk Ye, B; Jung, KW; Kim, JH; Kim, KJ; Lee, SO; Myung, SJ; Park, SK; Sik Yu, C; Yang, DH; Yang, SK, 2014) |
| "Ciprofloxacin/metronidazole was more cost-effective compared with piperacillin/tazobactam (2200 US dollars-3600 US dollars lower cost-effective ratios per patient) regardless of whether the patient had a diagnosis of appendicitis or whether a switch to an oral drug was permissible." | 2.42 | Use of ciprofloxacin in the treatment of hospitalized patients with intra-abdominal infections. ( Madan, AK, 2004) |
| "For optimal treatment, abdominal abscesses require prompt drainage and properly selected antibiotics at adequate doses." | 1.37 | Impact of evaluating antibiotic concentrations in abdominal abscesses percutaneously drained. ( Barshikar, S; Baylor, AE; Dolman, HS; Glowniak, J; Hong, K; Lavery, T; Nailor, M; Singla, R; Stassinopoulus, J; Tyburski, JG; Wilson, RF; Zimmerman, LH, 2011) |
| "metronidazole (MTR) was compared with i." | 1.32 | Results of a prospective, randomized, double blind comparison of the efficacy and the safety of sequential ciprofloxacin (intravenous/oral)+metronidazole (intravenous/oral) with ceftriaxone (intravenous)+metronidazole (intravenous/oral) for the treatment ( Asimakopoulos, C; Bassaris, H; Harlaftis, N; Karravias, D; Kolaras, P; Nikolaidis, P; Skoutelis, A; Starakis, I, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (58.33) | 29.6817 |
| 2010's | 3 (25.00) | 24.3611 |
| 2020's | 2 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Arezzo, A | 1 |
| Nicotera, A | 1 |
| Bonomo, LD | 1 |
| Olandese, F | 1 |
| Veglia, S | 1 |
| Ferguglia, A | 1 |
| Pentassuglia, G | 1 |
| Mingrone, G | 1 |
| Morino, M | 1 |
| Kobayashi, T | 1 |
| Bogdanic, F | 1 |
| Pujagic, E | 1 |
| Goto, M | 1 |
| Park, SK | 1 |
| Kim, KJ | 1 |
| Lee, SO | 1 |
| Yang, DH | 1 |
| Jung, KW | 1 |
| Duk Ye, B | 1 |
| Byeon, JS | 1 |
| Myung, SJ | 1 |
| Yang, SK | 1 |
| Kim, JH | 1 |
| Sik Yu, C | 1 |
| Kuriyama, A | 1 |
| Paladino, JA | 1 |
| Gilliland-Johnson, KK | 1 |
| Adelman, MH | 1 |
| Cohn, SM | 2 |
| Zimmerman, LH | 1 |
| Tyburski, JG | 1 |
| Glowniak, J | 1 |
| Singla, R | 1 |
| Lavery, T | 1 |
| Nailor, M | 1 |
| Stassinopoulus, J | 1 |
| Hong, K | 1 |
| Barshikar, S | 1 |
| Dolman, HS | 1 |
| Baylor, AE | 1 |
| Wilson, RF | 1 |
| Starakis, I | 1 |
| Karravias, D | 1 |
| Asimakopoulos, C | 1 |
| Kolaras, P | 1 |
| Nikolaidis, P | 2 |
| Harlaftis, N | 1 |
| Skoutelis, A | 1 |
| Bassaris, H | 2 |
| Artiko, V | 1 |
| Obradović, V | 1 |
| Davidović, B | 1 |
| Petrović, M | 1 |
| Nikolić, N | 1 |
| Petrović, N | 1 |
| Vlajković, M | 1 |
| Matić, S | 1 |
| Kecmanović, D | 1 |
| Bosnjaković, V | 1 |
| Milovanović, V | 1 |
| Madan, AK | 1 |
| Wacha, H | 1 |
| Warren, B | 1 |
| Hung, PH | 1 |
| Chiu, YL | 1 |
| Hsueh, PR | 1 |
| Lipsett, PA | 1 |
| Buchman, TG | 1 |
| Cheadle, WG | 1 |
| Milsom, JW | 1 |
| O'Marro, S | 1 |
| Yellin, AE | 1 |
| Jungerwirth, S | 1 |
| Rochefort, EV | 1 |
| Haverstock, DC | 1 |
| Kowalsky, SF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Antibiotic Irrigations for Intra-Abdominal Drains[NCT03476941] | Phase 2 | 50 participants (Anticipated) | Interventional | 2019-04-01 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for ciprofloxacin and Abdominal Abscess
| Article | Year |
|---|---|
Use of ciprofloxacin in the treatment of hospitalized patients with intra-abdominal infections.
Topics: Abdominal Abscess; Anti-Infective Agents; Ciprofloxacin; Drug Therapy, Combination; Gram-Negative Ba | 2004 |
3 trials available for ciprofloxacin and Abdominal Abscess
| Article | Year |
|---|---|
Pharmacoeconomics of ciprofloxacin plus metronidazole vs. piperacillin-tazobactam for complicated intra-abdominal infections.
Topics: Abdominal Abscess; Adult; Aged; Anti-Bacterial Agents; Appendicitis; Ciprofloxacin; Cost-Benefit Ana | 2008 |
Comparison of sequential intravenous/oral ciprofloxacin plus metronidazole with intravenous ceftriaxone plus metronidazole for treatment of complicated intra-abdominal infections.
Topics: Abdomen; Abdominal Abscess; Administration, Oral; Anti-Bacterial Agents; Bacterial Infections; Cipro | 2006 |
Comparison of intravenous/oral ciprofloxacin plus metronidazole versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections.
Topics: Abdomen; Abdominal Abscess; Administration, Oral; Anti-Infective Agents; Appendicitis; Bacterial Inf | 2000 |
8 other studies available for ciprofloxacin and Abdominal Abscess
| Article | Year |
|---|---|
Outcomes of surgical treatment of diverticular abscesses after failure of antibiotic therapy.
Topics: Abdominal Abscess; Abscess; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Ci | 2023 |
Isolated splenic abscess due to
Topics: Abdominal Abscess; Adult; Anti-Bacterial Agents; Ceftriaxone; Ciprofloxacin; Humans; Male; Salmonell | 2020 |
Ciprofloxacin usage and bacterial resistance patterns in Crohn's disease patients with abscesses.
Topics: Abdominal Abscess; Adolescent; Adult; Anti-Bacterial Agents; Ciprofloxacin; Crohn Disease; Drainage; | 2014 |
Chestnut Sign: Metronidazole-Induced Encephalopathy.
Topics: Abdominal Abscess; Aged; Anti-Bacterial Agents; Ataxia; Brain Diseases; Ciprofloxacin; Depression; D | 2017 |
Impact of evaluating antibiotic concentrations in abdominal abscesses percutaneously drained.
Topics: Abdominal Abscess; Aged; Aged, 80 and over; Anti-Bacterial Agents; Cefepime; Cephalosporins; Ciprofl | 2011 |
Results of a prospective, randomized, double blind comparison of the efficacy and the safety of sequential ciprofloxacin (intravenous/oral)+metronidazole (intravenous/oral) with ceftriaxone (intravenous)+metronidazole (intravenous/oral) for the treatment
Topics: Abdominal Abscess; Adult; Aged; Bacterial Infections; Ceftriaxone; Ciprofloxacin; Double-Blind Metho | 2003 |
[Detection of abdominal infections using radio-labeled antibiotics].
Topics: Abdomen; Abdominal Abscess; Anti-Infective Agents; Bacterial Infections; Ciprofloxacin; Humans; Radi | 2003 |
Gas-forming splenic abscess due to Salmonella enterica serotype Enteritidis in a chronically hemodialyzed patient.
Topics: Abdominal Abscess; Anti-Bacterial Agents; Bacteremia; Ceftriaxone; Ciprofloxacin; Humans; Male; Midd | 2007 |